SCHEMBL14197656

SCHEMBL14197656

COC(=O)c1cscc1NCl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.45
MAPK9 P45984 1/20 0.45
MAPK10 P53779 1/20 0.45
KDM4E B2RXH2 3/20 0.39
POLB P06746 1/20 0.39
ATM Q13315 1/20 0.39
PTPN1 P18031 1/20 0.38
TSHR P16473 2/20 0.37
LMNA P02545 1/20 0.37
ALDH1A1 P00352 3/20 0.36
CFTR P13569 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ABL1 P00519 1/20 0.36
MAPT P10636 1/20 0.36
ALOX15 P16050 1/20 0.36
KMT2A Q03164 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
CYP2A6 P11509 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68934 0.81 TSHR (0.46) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL6220756 0.79 MAPT (0.51) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL2394883 0.78 MAPK8 (0.43) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL4066272 0.78 MAPK8 (0.52) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL3563299 0.78 MAPK10 (0.55) MAPK8MAPK9MAPK10KDM4EPTPN1
SCHEMBL11371753 0.77 PTGS2 (0.49) MAPK8MAPK9MAPK10POLBTSHR
SCHEMBL3554545 0.76 MAPK8 (0.45) MAPK8MAPK9MAPK10KDM4EPTPN1
SCHEMBL18047964 0.76 GSK3B (0.52) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL3056644 0.76 TSHR (0.39) MAPK8MAPK9MAPK10KDM4EPOLB
SCHEMBL10076110 0.75 MAPK10 (0.56) MAPK8MAPK9MAPK10KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080139551-A1 TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES AVANIR PHARMACEUTICALS (US) 2008-06-12 US disclosed
US-7365200-B2 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS (US) 2008-04-29 US disclosed
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS MIF, MMP12, MSR1 MAPK8 2352/4885MAPK9 2247/4885MAPK10 3177/4885
US-20080139551-A1 TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES TNF, TNFRSF1A, TNFRSF9 MAPK8 4011/4885MAPK9 4598/4885MAPK10 3867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.